Pharma Marketing Network

Congrats to Thibaud Guymard (@thibaudguymard), Digital Marketing Manager at MSD France, and his Comuniti team for winning the Prix Or de la Communication...

FDA/CDER has published its 2015 Guidance Agenda (here). Here's what's under the Advertising Category: Brief Summary and Adequate Directions for Use: Disclosing Risk Information in...

In 2014, the FDA approved 41 new drugs -- the most since 1996 (see here). That's quite a "record" even if 37% of the...

This article summarizes the results of the KOL Name Change Survey and discusses how to change the underlying process by which pharma companies choose KOLs.

The FDA approved a total of 41 new molecular entities (NMEs) and biologics (BLAs) in 201 4but sent out only a meager 10 advertising enforcement letters in 2014, the fewest ever.

Here's John Mack's list of 2015 resolutions for pharmaceutical marketers. Hopefully, at least one of these will be kept, although no one is making any promises.

In this article, Pharmaguy presents the best images from Pharma Marketing Blog, which cover topics of importance in 2014: DTC and drug promotion spending, drug risks and adverse events, drug industry reputation, FDA and social media regulatory guidelines, mobile apps, and drug development costs.

Welcome to Volume 14, Issue #1 (JANUARY 2015) of Pharma Marketing News.

My #1 New Year's Resolution is the same every year:  Stop telling pharmaceutical marketers what to do all the time. Unfortunately, I have never kept that...

The ad shown on the left is the subject of an FDA/OPDP "untitled letter" (definition), which took aim at a Sunovion professional print ad...